Dificid Launch On Path To Success
This article was originally published in The Pink Sheet Daily
Optimer Pharmaceuticals’ antibiotic Dificid is on track to exceed one-year targets agreed upon with co-promotion partner Cubist.
You may also be interested in...
The antibiotic drug developer has been actively marketing its drug since it was approved last year, but it makes a more concerted effort to address issues of costs in hospitals, it said during at analyst day.
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxicity antidote Voraxaze.
A year after FDA approval of its antibiotic Dificid, the Optimer board has ousted its chairman and at least two other top executives.